Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176157 | PMC |
| http://dx.doi.org/10.1186/s13054-022-04038-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune responses to SARS-CoV-2 in sub-Saharan Africa and western Europe: a retrospective, population-based, cross-sectional study.
Lancet Microbe
December 2024
Leiden University Center for Infectious Diseases Leiden University Medical Centre, Leiden, Netherlands. Electronic address:
Background: SARS-CoV-2 has been associated with a higher proportion of asymptomatic infections and lower mortality in sub-Saharan Africa than high-income countries. However, there is currently a lack of data on cellular immune responses to SARS-CoV-2 in people living in Africa compared with people in high-income regions of the world. We aimed to assess geographical variation in peripheral and mucosal immune responses.
View Article and Find Full Text PDFValidation of an interferon-gamma enzyme-linked immunosorbent spot assay to evaluate cell-mediated immunity against severe acute respiratory syndrome coronavirus 2.
Hum Vaccin Immunother
December 2024
Department of Microbiology, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
The COVID-19 pandemic forced the rapid development of methods to measure humoral and cellular immunity against SARS-CoV-2. The lack of a global standardized protocol and the high variability of intra- and inter-assay precision of the T-cell response made it difficult to compare T-cell assay results with those of other laboratories. The interferon-gamma enzyme-linked immunosorbent spot (IFN-γ ELISpot) assay for immunogenicity evaluation was validated using naturally infected donor peripheral blood mononuclear cells, a commercially available IFN-γ ELISpot kit, and a SARS-CoV-2 specific peptide pool.
View Article and Find Full Text PDFA Facile Synthesis of 3-Substituted Coumarins and Investigation of Their 3CLpro Inhibition Activity Against SARS-CoV-2.
ChemistryOpen
November 2024
Bio-Organic Division, Bhabha Atomic Research Centre, Mumbai, 400085, India.
The major threat to public health due to the outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been recognised as a global issue. The increase in morbidity is primarily due to the lack of SARS-CoV-2 specific drugs. One of the major strategies to combat this threat is to deactivate the enzymes responsible for the replication of corona virus.
View Article and Find Full Text PDFHigh Somatization Rates, Frequent Spontaneous Recovery, and a Lack of Organic Biomarkers in Post-Covid-19 Condition.
Brain Behav
October 2024
Department of Neurology, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.
Article Synopsis
- Many patients experience neuropsychiatric symptoms post-SARS-CoV-2 infection, but the prevalence of post-COVID-19 condition (PCC) is inconsistent due to vague diagnostic criteria and nonspecific symptoms.
- A study followed 175 PCC patients for up to 18 months, revealing common symptoms like fatigue, stress intolerance, and cognitive deficits, with 28% also diagnosed with psychiatric disorders.
- Over time, most patients showed improvement, with 76.8% reporting reduced symptoms and 51.2% symptom-free, while testing did not support the role of suggested biomarkers in identifying PCC.
Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4 T-Cell Lymphopenia but Preserved Responses to CMV.
Vaccines (Basel)
April 2024
Division of Immunology, Hospital General Universitario "Gregorio Marañón", 28007 Madrid, Spain.
Immunogenicity of SARS-CoV-2 mRNA vaccines is highly heterogeneous in patients with inborn errors of immunity (IEIs). This case report analyzes the immune response to mRNA COVID-19 two-dose primary vaccination followed by three boosters in an IEI patient with marked CD4 T-cell cytopenia and diminished thymic output, in comparison with that raised against latent, chronic cytomegalovirus (CMV) infection. Serum IgG antibodies anti-spike (S) protein of SARS-CoV-2 and anti-CMV were both determined by chemiluminescent microparticle immunoassays (CMIAs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!